pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

297 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT813Endpoints614BioPharma Dive235onclive165Fierce Biotech81BioSpace79raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC
    AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.
    onclive · 2mo ago↗ source
  • Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis
    Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.
    onclive · 2mo ago↗ source
  • Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention
    Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.
← prev
page 7 of 12
next →
fda press21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026
    Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.
    onclive · 2mo ago↗ source
  • Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
    Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
    onclive · 2mo ago↗ source
  • Imaging Clues That Raise Suspicion for Diffuse Midline Glioma
    n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG.
    onclive · 2mo ago↗ source
  • Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification
    In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.
    onclive · 2mo ago↗ source
  • Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance
    Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.
    onclive · 2mo ago↗ source
  • Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC
    Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.
    onclive · 2mo ago↗ source
  • Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
    The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
    onclive · 2mo ago↗ source
  • Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
    A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.
    onclive · 2mo ago↗ source
  • REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
    Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
    onclive · 2mo ago↗ source
  • Clinical Implementation and Surveillance Strategies
    onclive · 2mo ago↗ source
  • Case Introduction and ctDNA as Emerging Risk Factor
    onclive · 2mo ago↗ source
  • ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
    Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.
    onclive · 2mo ago↗ source
  • MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies
    Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.
    onclive · 2mo ago↗ source
  • Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question
    New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.
    onclive · 2mo ago↗ source
  • HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response
    HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.
    onclive · 2mo ago↗ source
  • Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
    Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
    onclive · 2mo ago↗ source
  • Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss
    How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.
    onclive · 2mo ago↗ source
  • Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer
    Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.
    onclive · 2mo ago↗ source
  • Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies
    Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.
    onclive · 2mo ago↗ source
  • Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
    Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.
    onclive · 2mo ago↗ source
  • FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
    The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
    onclive · 2mo ago↗ source
  • FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
    The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.
    onclive · 2mo ago↗ source